NYSE: DDDuPont

    DuPont Q3 2026 Results: Net Income $123 Million on Revenue of $1.87 Billion

    • US stocks
    • Earnings
    • Industrials
    A chemical plant seen across a grassy field under a clear blue sky, with pipework, a white process building and rows of storage silos.
    Benoît Prieur, via Wikimedia Commons (CC0). Illustrative image.

    DuPont (NYSE: DD) reported results for the third quarter of 2026, the three months to 30 Sep 2026, and it said on 3 Nov 2026 that GAAP net sales were $1.87 billion and GAAP net income attributable to common stockholders was $123.0 million. GAAP diluted EPS was $0.91, and adjusted EPS, a company-defined measure, was $2.09.

    Key highlights

    • Net sales (GAAP): $1.87 billion, up 4.1% YoY and 2.7% QoQ
    • Net income (GAAP, attributable to common stockholders): $123.0 million, against a loss of $123.0 million YoY and down 14.0% QoQ
    • Diluted EPS (GAAP): $0.91, against a loss of $0.88 YoY
    • Adjusted EPS (company-defined): $2.09, up 62% YoY
    • Transaction-adjusted free cash flow (company-defined): $341 million, down 1% YoY

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue1,868.01,795.0+4.1%1,819.0+2.7%
    123.0-123.0n/a143.0-14.0%
    Diluted EPS ($)0.91-0.88n/a1.05-13.3%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP net sales up 4.1% from a year earlier and up 2.7% from the previous quarter. The company said organic sales rose 5%, with currency a 1% headwind.

    The GAAP net income margin was 6.6%, against -6.9% a year earlier, which is 13.5 percentage points higher. Net income fell 14.0% from the previous quarter.

    Adjusted figures exclude significant items and amortization

    The company's adjusted earnings were $282 million, against $180 million a year earlier. Significant items were $22 million pre-tax, led by acquisition, integration and separation costs of $15 million and restructuring charges of $6 million, and the release attributes a $43 million net income tax item to tax charges tied to a research and development expensing election and non-tax deductible items. The company's adjusted measures also exclude amortization of intangibles, $68 million pre-tax in the quarter.

    Segments, cash flow and guidance raised

    Healthcare & Water Technologies net sales were $865 million, up 4%, with operating EBITDA of $263 million and a 30.4% margin. Diversified Industrials net sales were $1,003 million, up 4%, with operating EBITDA of $242 million and a 24.1% margin. The company said third quarter 2025 net sales had included a $15 million benefit from an order timing shift.

    Cash provided by operating activities from continuing operations was $410 million. The company said it finished a $250 million accelerated share purchase and most of a $100 million open market buyback during the quarter. The company now expects full-year 2026 net sales of about $7,190 million, operating EBITDA of about $1,785 million and adjusted EPS of $7.47 to $7.52, with organic growth of about 4.5%.

    Inference

    Diluted weighted-average shares were 135.1 million, against 140.0 million a year earlier. Nine-month purchases of common stock and forward contracts were $611 million, and dividends paid to stockholders in the nine months were $243 million.

    The company intends to repurchase $250 million of shares in the fourth quarter of 2026. The release does not state a dividend declared in the quarter or give the previous guidance ranges as numbers.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts